ICON Public Limited Company

NasdaqGS ICLR

ICON Public Limited Company Gross Profit for the year ending December 31, 2023: USD 2.40 B

ICON Public Limited Company Gross Profit is USD 2.40 B for the year ending December 31, 2023, a 8.39% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • ICON Public Limited Company Gross Profit for the year ending December 31, 2022 was USD 2.21 B, a 46.82% change year over year.
  • ICON Public Limited Company Gross Profit for the year ending December 31, 2021 was USD 1.51 B, a 86.65% change year over year.
  • ICON Public Limited Company Gross Profit for the year ending December 31, 2020 was USD 808.03 M, a -2.85% change year over year.
  • ICON Public Limited Company Gross Profit for the year ending December 31, 2019 was USD 831.70 M, a 8.09% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
NasdaqGS: ICLR

ICON Public Limited Company

CEO Dr. Steven A. Cutler MBA, Ph.D.
IPO Date May 15, 1998
Location Ireland
Headquarters South County Business Park
Employees 42,250
Sector Industrials
Industries
Description

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Similar companies

QGEN

Qiagen N.V.

USD 45.57

-0.94%

MEDP

Medpace Holdings, Inc.

USD 330.91

-5.99%

NEOG

Neogen Corporation

USD 12.00

-5.06%

IQV

IQVIA Holdings Inc.

USD 197.96

-3.26%

LH

Laboratory Corporation of America Holdings

USD 234.50

0.17%

WAT

Waters Corporation

USD 404.93

1.26%

CRL

Charles River Laboratories International, Inc.

USD 178.08

-6.34%

TWST

Twist Bioscience Corporation

USD 42.75

-1.91%

MTD

Mettler-Toledo International Inc.

USD 1.27 K

0.33%

StockViz Staff

January 15, 2025

Any question? Send us an email